Sign In
Buy NKTR
$72.76
+2.17 (+3.07%)
At Close: Aug 04, 2026
3 Stocks Wall Street Thinks Will Soar 50% or More in 2021
06:08am, Sunday, 24'th Jan 2021
These stocks have one obvious thing in common.
Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference
05:00pm, Wednesday, 06'th Jan 2021
SAN FRANCISCO, Jan. 6, 2021 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 39th Annual J.P. Morgan Vir
35% Upside Likely For Nektar Therapeutics?
08:00am, Wednesday, 06'th Jan 2021
We believe that Nektar Therapeutics stock, a biopharmaceutical company focused on discovering and developing medicines in areas that include cancer, autoimmune disease, and chronic pain, is a good buy
Stocks making the biggest moves after the bell: Cal-Maine Foods, Myriad Genetics & more
04:47pm, Tuesday, 05'th Jan 2021
These are the stocks posting the largest moves after hours on Tuesday.
Nektar Appoints Dr. Brian Kotzin as Interim Chief Medical Officer and Head of Development
04:20pm, Tuesday, 05'th Jan 2021
SAN FRANCISCO, Jan. 5, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today that it has appointed Brian Kotzin, MD as Interim Chief Medical Officer, Head of Development effective im
Implied Volatility Surging for Nektar Therapeutics (NKTR) Stock Options
12:02pm, Tuesday, 22'nd Dec 2020
Investors need to pay close attention to Nektar Therapeutics (NKTR) stock based on the movements in the options market lately.
Nektar Therapeutics: A Look At The SITC BEMPEG Data
01:23am, Friday, 20'th Nov 2020
Nectar, a global leader in polymer chemistry-based drug discovery, has no major near-term catalysts, a vast pipeline and numerous big pharma collaborations. It recently published a set of 3 trial data
SAN FRANCISCO, Nov. 11, 2020 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced four data presentations for its I-O pipeline from three separate clinical-stage investigational agents a
Nektar Therapeutics (NKTR) CEO Howard Robin on Q3 2020 Results - Earnings Call Transcript
11:57pm, Thursday, 05'th Nov 2020
Nektar Therapeutics (NKTR) CEO Howard Robin on Q3 2020 Results - Earnings Call Transcript
SAN FRANCISCO, Nov. 4, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced the presentation of additional clinical data from the Phase 1b study evaluating multiple ascending doses of NKTR
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors for 2020 American College of Rheumatology (ACR) Congress
06:00pm, Thursday, 29'th Oct 2020
SAN FRANCISCO, Oct. 29, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today that it will webcast an analyst and investor conference call at ACR 2020 with company management and Dr.
Nektar to Announce Financial Results for the Third Quarter 2020 on Thursday, November 5, 2020, After Close of U.S.-Based Financial Markets
06:00pm, Wednesday, 28'th Oct 2020
SAN FRANCISCO, Oct. 28, 2020 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2020 on Thursday, November 5, 2020, after the close of U.S.-ba
DAVENPORT & Co LLC Sells 4,250 Shares of Nektar Therapeutics (NASDAQ:NKTR)
06:10am, Monday, 19'th Oct 2020
DAVENPORT & Co LLC decreased its holdings in Nektar Therapeutics (NASDAQ:NKTR) by 6.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 58,300 sh
Nektar Therapeutics (NASDAQ:NKTR) Stock Rating Upgraded by BidaskClub
01:12am, Saturday, 10'th Oct 2020
Nektar Therapeutics (NASDAQ:NKTR) was upgraded by equities researchers at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued on Saturday, BidAskClub reports.
Charles Schwab Investment Management Inc. Raises Stake in Nektar Therapeutics (NASDAQ:NKTR)
08:58am, Monday, 28'th Sep 2020
Charles Schwab Investment Management Inc. boosted its holdings in shares of Nektar Therapeutics (NASDAQ:NKTR) by 11.0% during the 2nd quarter, according to its most recent 13F filing with the SEC. The
